Sales growth (+201TP3Q), EBITDA positive in the second half and close to breakeven for the full year

IntegraGen today announces its financial results for the year ended December 31, 2019. The financial statements were approved by the Board of Directors, which met on April 2, 2020.

• EBITDA of €255,000 in the second half of 2019, down to -€70,000 for the full year
• Sustained business growth in 2019: +20%

- SeqOIA sequencing platform starts operations

- Increase in business at Institut Pasteur

• Acceleration of sales of software for genomic data interpretation
• Implement measures to ensure business continuity during the Covid-19 pandemic, maintain genomics activity and preserve financial resources

To the press release

---

April 03, 2020

Share :

---

• IntegraGen Update - Always open for your projects
• IntegraGen achieves CE mark for MERCURY™ cloud-based software application for interpreting tumor molecular data from Cancer patients